Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells

J Lipid Res. 2003 Oct;44(10):1963-75. doi: 10.1194/jlr.M300188-JLR200. Epub 2003 Jul 1.

Abstract

Lysophosphatidic acid (LPA) is a receptor-active lipid mediator with a broad range of biological effects. Ovarian cancer cells synthesize LPA, which promotes their motility, growth, and survival. We show that a murine homolog of a human protein previously reported to hydrolyze LPA is a highly selective detergent-stimulated LPA phosphatase that can be used to detect and quantitate LPA. Use of this protein in novel enzymatic assay demonstrates that SK-OV-3 ovarian cancer cells release physiologically relevant levels of biologically active LPA into the extracellular space. LPA release is markedly increased by nucleotide agonists acting through a P2Y4 purinergic receptor. Promotion of LPA formation by nucleotides is accompanied by stimulation of phospholipase D (PLD) activity. Overexpression of both PLD1 and PLD2 in SK-OV-3 cells produces active enzymes, but only overexpression of PLD2 results in significant amplification of both nucleotide-stimulated PLD activity and LPA production. SK-OV-3 cells express and secrete a phospholipase A2 activity that can generate LPA from the lipid product of PLD, phosphatidic acid. Our results identify a novel role for nucleotides in the regulation of ovarian cancer cells and suggest an indirect but critical function for PLD2 in agonist-stimulated LPA production.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine Triphosphate / pharmacology
  • Animals
  • Antineoplastic Agents / pharmacology*
  • Base Sequence
  • Cell Division / drug effects
  • Female
  • Humans
  • Lysophospholipids / biosynthesis*
  • Molecular Sequence Data
  • Nucleotides / metabolism
  • Ovarian Neoplasms / metabolism*
  • Phospholipase D / metabolism*
  • Phospholipase D / pharmacology
  • Phospholipases A / metabolism
  • Phospholipases A2
  • Receptors, Cell Surface / agonists*
  • Receptors, Purinergic / metabolism
  • Reverse Transcription
  • Sequence Alignment
  • Suramin / pharmacology
  • Time Factors
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Lysophospholipids
  • Nucleotides
  • Receptors, Cell Surface
  • Receptors, Purinergic
  • Suramin
  • Adenosine Triphosphate
  • Phospholipases A
  • Phospholipases A2
  • Phospholipase D